Startup profile · funding coverage
Recursion
AI-enabled drug discovery and digital biology platform.
Stage
public
Status
public
Coverage
full
Why Recursion is interesting
Industrialized phenomics at scale — Lux and CRV in rounds; a16z on investment list without named syndicate in press reviewed.
Key facts
- Series A (2016): $13M led by Lux (Lux Capital)
- Series B (2017): $60M led by DCVC; Lux, Menlo, CRV, Two Sigma among participants (TechCrunch)
- IPO (2021): NASDAQ: RXRX
Investors in our directory
Funds linked from Recursion's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Market / IPO context
Ticker: RXRX (NASDAQ)
IPO status: public
Editorial / static context — not a live quote.
FAQs about Recursion
Funding context and why this company shows up in venture coverage.
Recursion is listed among Andreessen Horowitz (a16z) investments on a16z’s public investment list.
We track a16z-backed companies that are strategically relevant for founders and investors following AI, American Dynamism, crypto, bio, and enterprise software.
Last updated: 2026-07-24